DataM Intelligence | competitive Intelligence CIDP treatment evolves with novel approvals like Vyvgart Hytrulo and HYQVIA, offering patient ...

慢性炎症性脱髓鞘性多发性神经病（CIDP）长期以来被定义为一种纯粹累及周围神经系统的自身免疫性疾病，典型表现为四肢对称性无力和感觉障碍。然而临床观察中，患者常抱怨"脑子转得慢"或"记不住事"，这些现象用传统病理机制难以解释。更令人困惑的是，作为神经轴索损伤标志物的血清神经丝轻链（sNfL）在CIDP患者中异常升高——这本是阿尔茨海默病、多发性硬化等中枢神经系统疾病的特征性改变。这些矛盾现象引发了一 ...

Retinitis Pigmentosa therapies evolve beyond gene-specific fixes with gene-agnostic, intravitreal, and optogenetic advances ...

Intellia’s stock fell 23% after one patient in its Phase III MAGNITUDE trial developed severe liver toxicity that later ...

Shares of Intellia Therapeutics NTLA were down 22.9% yesterday after it announced an update from the ongoing phase III study, ...

Correspondence to Dr Satoshi Kuwabara, Department of Neurology, Graduate School of Medicine, Chiba University 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan; kuwabara-s{at}faculty.chiba-u.jp While ...

Shares of Intellia Therapeutics fell after the company reported a grade 4 adverse event in a study of nex-z, its treatment for hereditary ATTR amyloidosis with polyneuropathy. The stock was down 24% ...

The clinical-stage immunology company reported a net loss of $0.64 per share for the quarter, lower than an estimated loss of ...

Intellia Therapeutics’ stock may have taken a hit in the wake of details of a grade 4 adverse event in a phase 3 trial, but ...